September 8, 2017Open Access

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Antonia et al. (Fri,) studied this question.

www.synapsesocial.com/papers/699562f810cb51f425ec45ec — DOI: https://doi.org/10.1056/nejmoa1709937

Authors

Scott Antonia

Augusto Villegas

Davey B. Daniel

Journals

New England Journal of Medicine

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion